56 results about "Substance use" patented technology

The present invention provides, in part, methods of treatment for substance use disorder comprising applying repetitive transcranial magnetic stimulation (rTMS) therapy to a patient in need thereof. The present invention also provides devices that generate a low intensity pulsed magnetic field and variable frequencies.

Provided herein are non-naturally occurring melanocortin analogs that selectively bind at least a portion of a melanocortin receptor The melanocortin receptor may be a melanocortin 3 receptor (MC3R) or a melanocortin 4 receptor (MC4R). The non-naturally occurring melanocortin analogs may have a dissociation constant (Kd) value for a melanocortin receptor or one or more amino acids thereof that is less than that of a conventional melanocortin analog.

The invention provides a compound used as a CaV1.22 activating agent. In particular, a compound according to formula (I) or a pharmaceutically acceptable salt thereof is provided as a CaV1.22 activator for the treatment of schizophrenia, bipolar disorder, severe depressive disorder, substance use disorder, ADHD, Ferren-Mecdemedes syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Bruggea syndrome, short QT syndrome, and the like. Or early repolarization syndrome. # imgabs0 #

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

A device for inhaling powder-type substances includes a plurality of substance containers that can be moved successively into an emptying position, wherein the substance containers—which are not connected to one another—are accommodated in direct contact with one another in a guide unit attached to the device and can be moved by contact pressure propagating among the substance containers. The guide unit has a drive wheel with accommodating forms separated by drive teeth. The substance container in the emptying position is located in an accommodating form of the drive wheel. A substance container for a device for inhaling powder-type substances has two sub-regions, each separately having an amount of the substance, and both sub-regions have an openable, pierceable cover. A method for filling a device for inhaling powder-type substances uses a plurality of substance containers that can be moved successively into an emptying position.

The present disclosure provides for a compound according to formula (I)or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).

The present invention discloses a system and method for managing treatment plans and clinical documentation for substance use disorder (SUD) treatment. The system includes user devices associated with clients, clinicians, organization representatives, and supervisors. The system connects to a database storing client data, clinician data, assessment scores, and clinical documentation such as SOAP notes and progress notes. A computing device with artificial intelligence (AI) modules executes various program modules. A data collection module guides clinicians through predefined questions to gather information for generating SOAP and clinical progress notes. A secondary data collection module collects clarification from the counselor without requiring client input. A review module allows counselors to review, edit, approve, and submit documentation. A treatment plan generation module creates or updates plans based on collected data and prior scores. The system improves documentation efficiency, quality, and compliance, while supporting accurate and personalized treatment planning.

The present invention discloses a system for managing treatment of behavioral health conditions including substance use disorder (SUD). The system comprises a computing device in communication with a database and user devices via a network. The computing device provides a questionnaire comprising a plurality of categories. Each category comprises a set of questions to assess progress of the client. The computing device enables a clinician to input a score for each question based on analyzing response of client to each question. The computing device is configured to apply predefined scoring guidelines for the input score and generate the score data including the category score data for each category and the recovery score data for the questionnaire. The computing device enables the clinician to continuously evaluate and track the progress of the client, and provide a treatment plan based on current score data and progress data of the client.

Provided herein are non-naturally occurring melanocortin analogs that selectively bind at least a portion of a melanocortin receptor The melanocortin receptor may be a melanocortin 3 receptor (MC3R) or a melanocortin 4 receptor (MC4R). The non-naturally occurring melanocortin analogs may have a dissociation constant (Kd) value for a melanocortin receptor or one or more amino acids thereof that is less than that of a conventional melanocortin analog.

The present invention is directed to a method of treating a substance-use disorder (SUD) in a subject in need thereof, including administering to the subject a therapeutically effective amount of a pharmaceutical composition including bacteria, wherein at least 50% of the bacteria belong to a bacterial family being any one of: Ruminococcaceae, Rikenellaceae, and both, such as R. gnavus.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Certain embodiments are directed to methods of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a DMTU or a composition comprising same.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

Provided herein are non-naturally occurring melanocortin analogs or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof and compositions comprising the same. The melanocortin analogs are agonists or antagonists of melanocortin 3 and / or 4 receptors with sub-micromolar or low-nanomolar binding activity.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

A self-contained extended reality (XR) device is disclosed for real-time detection and mitigation of substance use disorder symptoms. The headset includes integrated biometric sensors for capturing physiological signals such as pupil dilation, heart rate, and head movement. A locally stored machine-learned model analyzes these signals to classify cognitive or affective states indicative of withdrawal, craving, or relapse risk. Upon detecting a threshold state, the headset automatically renders an immersive therapeutic environment selected to mitigate the user's condition. Interventions may include spatialized audio, visual modulation, and avatar-guided interactions. The device further supports adaptive personalization, secure local data storage, and optional transmission of session summaries to authorized care providers. The system operates without external computing devices and is optimized for privacy-preserving, user-specific behavioral health support.

Provided herein are systems and methods for presenting interventions to address substance use disorders (SUDs) in users. One or more processors may identify for a user with a substance use disorder, a profile including a plurality of substance use words, memory words, and neutral words. The one or more processors may provide a repeated cycle of selection activities and visualization activities. The one or more processors may update the profile of the user using the performance of the user in the activity. The systems and methods provided herein can enhance the efficacy of the medication that the user is taking in concurrence with addressing the SUD.

This application provides a gene construct and its uses, which is used to inhibit neuronal overexcitation caused by the overuse or abuse of addictive substances. The gene construct comprises a neuronal inhibitory protein-coding gene and a promoter operatively linked to the neuronal inhibitory protein-coding gene. The gene construct exhibits significant advantages in precise targeting, closed-loop regulation, preservation of natural reward responses, reduced side effects and improved safety, and potential long-term efficacy and sustainability. This strategy provides new ideas and methods for the treatment of substance use disorders and is expected to become a significant breakthrough in the field of substance use disorders in the future.

A diagnostic device includes a main enclosure having a subject end and an operator end at least one infrared light disposed within the main enclosure adjacent the subject end, at least one stimulus lens, at least one stimulus screen disposed adjacent the operator end having a front toward a subject and a back, a camera filter disposed adjacent the stimulus screen, a mirror, a camera mount disposed adjacent the back of the stimulus screen, and at least one camera coupled to the camera mount and directed toward the mirror.

The present disclosure relates generally to methods of treating various diseases, conditions, and conditions, such as depressive disorder (e.g., major depressive disorder (MDD)), substance use disorder, anxiety disorder, eating disorder, pain, and headache disorder, by administering deuterated gymnosin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.

The invention provides a compound used as a CaV1.22 activating agent. In particular, a compound according to formula (I) or a pharmaceutically acceptable salt thereof is provided as a CaV1.22 activator for the treatment of schizophrenia, bipolar disorder, severe depressive disorder, substance use disorder, ADHD, Ferren-Mecdemedes syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Bruggea syndrome, short QT syndrome, and the like. Or early repolarization syndrome. # imgabs0 #

Systems and methods disclosed herein relate generally to providing virtual reality (VR)-based therapeutic, user-specific treatment for substance use disorder (SUD). An exemplary method includes outputting, by a voice assistant of an audible output device of a VR device, a user prompt configured to trigger a dynamic session builder with a user experiencing SUD, analyzing, by the voice assistant, one or more vocal responses received from the user, inputting the one or more vocal responses into a generative AI model, generating, by the generative AI model based on the one or more vocal responses of the user received during the dynamic session builder, one or more immersive multimedia scenes and / or one or more audible statements, and outputting the one or more immersive multimedia scenes and / or the one or more audible statements.

The present invention is directed to a compound of Formula (I): where, A, R, R1, R2, Y, l, and n are as defined herein. The present invention is also directed to the use of these compounds for the treatment of pain, respiratory 5 depression, or mood or substance use disorders.

Provided herein are non-naturally occurring melanocortin analogs that selectively bind at least a portion of a melanocortin receptor The melanocortin receptor may be a melanocortin 3 receptor (MC3R) or a melanocortin 4 receptor (MC4R). The non-naturally occurring melanocortin analogs may have a dissociation constant (Kd) value for a melanocortin receptor or one or more amino acids thereof that is less than that of a conventional melanocortin analog.

Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterized by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.

Systems and methods are provided herein for providing intervention to address a user's substance use disorder (SUD). The one or more processors may identify a profile including a plurality of substance use words, memory words, and neutral words for a user having a substance use disorder. The one or more processors may provide repetitive cycles of selection activities and visualization activities. The one or more processors may update the user's profile using the user's performance in the activity. The systems and methods provided herein may enhance the efficacy of a medicament administered by a user while addressing SUD.